Enzene Targets Local Biomanufacturing with New Solutions
CDMO Enzene launched NeX™, which it labels “an end-to-end partnership model that enables governments, institutions, and biopharma organizations to establish world-class biomanufacturing capabilities wherever they need them.”
NeX, built on the EnzeneX®continuous manufacturing (FCCM™) platform, is designed to deliver a turnkey and scalable way to make biologics manufacturing transportable, close to patients and supply chains, while avoiding the capital burden of conventional fed‑batch facilities.
By enabling local FCCM‑based manufacturing, governments can significantly expand patient affordability and access to life‑saving biologics, according to Himanshu Gadgil, PhD, CEO of Enzene.
“A conventional biologics plant often requires between $300 million and $400 million to build,” he says. “With our fully-connected continuous manufacturing platform, the same output can be achieved for $60–$80 million. The efficiency comes from a compact, integrated system architecture rather than the scale-intensive layouts of fed-batch facilities, allowing for long-term cost advantage and high product yields for locally manufactured biomedicines.”
Enzene’s NeX program is intended to help regions accelerate the establishment of local biopharma capabilities and risk-mitigated supply chains, develop domestic scientific talent, and reduce long-term manufacturing costs for local patients, continues Gadgil, adding that the company estimates that facilities built under the program can achieve validation and commercial readiness in under three years.
NewsBiomanufacturingBiopharmaceuticalsEnZene BiosciencesEnzeneXNeX™Previous article
Fur Real: Biotech Startup Eliminates Major Dog Allergen in Beagle Pups Using CRISPRNext article
Electrical Stimulation’s Effects on Neurons, Gene Expression Mapped in Living Human Brain TissueAlso of Interest
Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE ProgramSmarter Cell Culture Starts with Better MediaTop 10 Contract Development and Manufacturing Organizations 2026AI Accelerates Biomanufacturing from Discovery to TranslationIncreasing CHO Cell ProductivityNo One-Size-Fits-All Solution for Autologous Cell Therapy ManufacturingRelated Media
Reporting Live from JPM 2026: Alex Philippidis and Jonathan Grinstein, PhDBoston and Bioprocessing: GEN Reports Live from the First Day at BPIEmerging Markets Collaborate to Succeed in Post-Pandemic WorldGlobal Single-Use Network Support Assurance of SupplyResins Address Downstream Purification ConcernsImproving Protein Therapeutic Production is a Key Goal of Biopharma 4.0Top 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
